CliffBio
biologic

Lumizyme

alglucosidase alfa

Loss of exclusivityMay 2022projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameLumizyme
Active ingredientalglucosidase alfa
Strength50MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2010
Marketing statusRx

More from Genzyme Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lumizyme patent cliff — loss of exclusivity May 2022 | CliffBio